An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Key Inclusion Criteria: * Histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastro-esophageal junction * Received first-line chemotherapy using fluoropyrimidine and platinum combination without disease progression * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease by modified WHO criteria (unless complete response from previous chemotherapy) Key Exclusion Criteria: * Known Human Epidermal growth factor Receptor2 (HER2) positive status * Radiological evidence of brain metastases * History of severe autoimmune or immune mediated disease requiring prolonged immunosuppressive treatment * Inadequate hematologic, renal and hepatic function